| Contact Us | About UsAdvertisement | 
Weather Forecast


Bluefish expands product portfolio further
Friday, 30 December 2011
Bluefish has signed a new license agreement for another 15 products. The portfolio now consists of 83 products, whereof 44 have been launched. The new products belong to a variety of therapeutic categories, including cardiovascular disease, depression, viral disease, oncology, inflammation and gastrointestinal disease, with an aggregated market value in the EU of SEK 46 billion.

The agreement is part of Bluefish long-term strategy to expand the product portfolio of generic versions of blockbusters as well as gradually offer a broader range of niche products within more narrow disease areas or to meet the demand for regional treatment principles.
The new products include Celecoxib, Duloxetine, Escitalopram, Esomeprazole, Famciclovir, Finasteride, Lamivudine, Moxifloxacin, Nebivolol, Nevirapine, Quetiapine SR, Rabeprazole, Telmisartan, Valsartan HCTZ and Valsartan.

“By growing the product portfolio, we secure sustainable long term growth for the company. The volumes in the blockbuster segments offer interesting opportunities to grow market share, while the niche products will allow Bluefish to enjoy higher margins in less competitive market segments”, says Karl Karlsson, CEO and founder of Bluefish.
The majority of the products will be submitted for registration during 2012 and will be launched gradually beginning in 2014.
Bases on a press release

| Print Friendly and PDF| Write to the editor | Complaint about this article | Make a Comment |
Swedband to cut workers more than previously thought

What do you think about the above article? Please leave us a comment and reaction. Thank you.TeliaSonera's credit rating is in danger
  • Should be Empty: